These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30201015)

  • 1. Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study.
    Franco P; De Bari B; Arcadipane F; Lepinoy A; Ceccarelli M; Furfaro G; Mistrangelo M; Cassoni P; Valgiusti M; Passardi A; Casadei Gardini A; Trino E; Martini S; Iorio GC; Evangelista A; Ricardi U; Créhange G
    Radiat Oncol; 2018 Sep; 13(1):172. PubMed ID: 30201015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
    Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
    Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
    Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
    Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
    Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
    Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
    De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM
    Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Integrated Boost (SIB) Versus Sequential Boost in Anal Cancer Patients: A Single-Center Experience.
    Khosla D; Kapoor R; Dey T; Kataria V; Singh R; Kumar D; Oinam AS; Gupta R; Rana SS; Shah J; Singh H; Irrinki S; Madan R
    J Gastrointest Cancer; 2024 Jun; 55(2):759-767. PubMed ID: 38236375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of toxicity in patients with anal cancer undergoing definitive simultaneous integrated boost (SIB) or sequential integrated boost (SeqB) radiotherapy.
    Rotondi M; Facondo G; Mossa S; Vullo G; Angelicone I; Valeriani M; Osti MF
    Int J Colorectal Dis; 2023 May; 38(1):125. PubMed ID: 37171509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer.
    Arcadipane F; Franco P; Ceccarelli M; Furfaro G; Rondi N; Trino E; Martini S; Iorio GC; Mistrangelo M; Cassoni P; Racca P; Morino M; Ricardi U
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):217-223. PubMed ID: 28856848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
    Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
    Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
    Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
    Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
    Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
    Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
    Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
    Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
    Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
    J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer.
    Mineur L; Vazquez L; Belkacemi M; Toullec C; Bentaleb N; Boustany R; Plat F
    Curr Oncol; 2023 Sep; 30(9):8563-8574. PubMed ID: 37754536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.